Separator
ASVINS Lifetechnologies: Driving Healthcare through Technology

ASVINS Lifetechnologies: Driving Healthcare through Technology

Separator
Samrat Marwah,Director -  Sales
Samrat Marwah,
Sales - Director

In most of the healthcare issues, the turn-around time for a patient to get the results usually after a biopsy sample is collected is almost 5-7 days or even more. In many instances, the patients have no choice but to travel from one part of the country to get their treatments done. However, due to long turn-around times of the results, the patients are forced to wait for their diagnosis reports so that the appropriate therapies can be started. ASVINS Life technologies provides a platform with which they are able to provide the diagnosis reports the same day to the physicians which enables them to start the appropriate therapies on their patients at an early stage.

Based in Lucknow – UP ASVINS Life technologies came into being in the year 2016 with a vision to enable molecular diagnostics and life sciences solutions on a centralized basis in India. The company is a part of the prestigious 60-year-old NSP group having diversified interests in Life sciences, Healthcare diagnostics and Blood Banking solutions. “We provide break through technology for healthcare and find new ways to deliver them to as many people as possible, speaks Samrat Marwah,
Sales - Director, ASVINS Life technologies.

ASVINS Life technologies aims to provide direct access to personalized medicine for patients in India by promoting fully integrated and broadly applicable molecular diagnostics. “Our platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients,” he informs.

"Idylla is a fully automated, real-time PCR based molecular diagnostics system designed to offer fast and easy access to clinical molecular diagnostic information - anywhere and anytime"

The company caters to Corporate/Private Cancer Hospitals, Super Speciality Hospitals, Government/Semi-Government Medical institutions focussing on cancer care, Corporate/Private Diagnostic service providers, Pharma companies who are providing various drugs for cancer treatment. “We try to guide the patients for early treatment of cancer which could save their lives from this deadly disease which is unfortunately at its peak today,” mentions Samrat.

Enabling Molecular Testing
To get their fastest fully automated Molecular Diagnostics platform named Idylla to the Indian market and accessible to the physicians for early diagnosis, ASVINS Life technologies has collaborated with one of the leading Molecular Dx company named Biocartis, NV, based in Belgium.

Idylla is a fully automated, real-time
PCR based molecular diagnostics system designed to offer fast and easy access to clinical molecular diagnostic information - anywhere and anytime. The platform covers the entire process from sample to result within 150 minutes with less than 2 minutes hands-on time. “Idylla detects and quantifies multiple DNA or RNA-based biomarkers in a wide variety of patient sample types. The fully integrated system enables clinical laboratories to perform a broad range of applications in oncology, infectious diseases and beyond. The Idylla™ system has obtained CE-IVD marking,” mentions Samrat.

ASVINS’s oncology assay offerings consists of a wide range of solid and liquid biopsy assays for Colorectal cancer, Lung cancer and Melanoma. Samrat adds, “Later this year, we would have solid biopsy assay for Microsatellite Instability(MSI) for colorectal cancer and liquid biopsy for Lung Cancer (EGFR).”

The Future Plans
ASVINS Life technologies has recorded a progressive growth in the revenues in the year 2017-18. With addition of more technically sound members in the team, the company now has PAN India presence in the healthcare industry. “At present, we are offering complete automated Solid and Liquid biopsies for Lung, Colon and skin cancer but soon would be dealing in MSI (Micro Satellite Instability) for determining lynch syndrome in Colon cancer, Breast Cancer (BRCA1 and BRCA 2) mutation test and Gene fusion panel for testing variety of other mutations like ALK, ROS1,” concludes Samrat.